Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Lowered by Leede Financial

Oncolytics Biotech (NASDAQ:ONCY) was downgraded by research analysts at Leede Financial from a “strong-buy” rating to a “moderate buy” rating in a report issued on Wednesday,Zacks.com reports.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Oncolytics Biotech in a research note on Thursday.

Oncolytics Biotech Trading Down 3.0 %

Oncolytics Biotech stock opened at $0.98 on Wednesday. Oncolytics Biotech has a 1-year low of $0.84 and a 1-year high of $1.75. The firm has a market capitalization of $75.53 million, a price-to-earnings ratio of -3.63 and a beta of 1.69. The firm’s fifty day moving average price is $1.09 and its two-hundred day moving average price is $1.06.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC purchased a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Oncolytics Biotech at the end of the most recent reporting period. 6.82% of the stock is currently owned by hedge funds and other institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.